Evidence map›Paper›PMID 34740891›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2022

In Defense of Current Concepts and Applications of Clearance in Drug Development and Therapeutics.

Malcolm Rowland, Michael S Roberts, K Sandy Pang

Abstract readComment
PubMed Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Are all measures of liver KpEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2024
    Article
  3. Article
  4. Process and System Clearances in Pharmacokinetic Models: Our Basic Clearance Concepts Are Correct.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  5. Drug metabolism and disposition: the biological fate of chemicals · 2022
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Malcolm RowlandCentre for Applied Pharmacokinetic Research, University of Manchester, Manchester, United Kingdom (M.R.); Therapeutics Research Centre, The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia (M.S.R.); UniSA Clinical and Health Sciences, Basil Hetzel Institute for Translational Health Research, University of South Australia, Adelaide, Australia (M.S.R.); and Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada (K.S.P.) mrow190539@aol.com.
Michael S RobertsCentre for Applied Pharmacokinetic Research, University of Manchester, Manchester, United Kingdom (M.R.); Therapeutics Research Centre, The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia (M.S.R.); UniSA Clinical and Health Sciences, Basil Hetzel Institute for Translational Health Research, University of South Australia, Adelaide, Australia (M.S.R.); and Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada (K.S.P.).
K Sandy PangCentre for Applied Pharmacokinetic Research, University of Manchester, Manchester, United Kingdom (M.R.); Therapeutics Research Centre, The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia (M.S.R.); UniSA Clinical and Health Sciences, Basil Hetzel Institute for Translational Health Research, University of South Australia, Adelaide, Australia (M.S.R.); and Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada (K.S.P.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clearance is one of the most widely quoted and applied pharmacokinetic concepts in drug development and therapy. Its foundations and associated models of drug elimination are well embedded and accepted within the scientific community. Recently, however, the prevailing views that have held us in good stead for the past almost 50 years have been challenged with the argument that organ clearance should not be based on elimination rate, now defined by extraction across the liver divided by incoming or systemic concentration, as in current practice, but rather, by the mean concentration of drug within the blood in the organ, which is model-dependent. We argue that all needed parameters already exist, and that the proposed new approach to organ clearance is confusing and unnecessary. SIGNIFICANCE STATEMENT: Clearance concepts are widely applied in drug development and therapy. Historically, hepatic clearance has been defined as the ratio of rate of elimination divided by ingoing blood concentration. Recently, this approach has been challenged arguing that clearance should be referenced to blood concentration within the liver extrapolation (IVIVE). There is no need for additional, a feature that corresponds to intrinsic clearance of the chosen clearance model, a widely accepted parameter in physiologically based pharmacokinetic (PBPK) and in vitro to in vivo extrapolation (IVIVE). There is no need for additional, confusing clearance terms, which offer no material benefit.

Indexed as

Drug DevelopmentModels, BiologicalKineticsLiverMetabolic Clearance Rate

Identifiers

PMID34740891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.